Achillion Announces Clearance of Investigational New Drug Application for ACH-5228

by NASDAQ Market News November 11, 2019

NASDAQ Market News
Click here to email author

BeyondSpring’s Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019

Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine

Ads